CYP2W1
Cytochrome P450 Family 2 Subfamily W Member 1
Gene Information Card
| Symbol | CYP2W1 |
|---|---|
| Full Name | Cytochrome P450 Family 2 Subfamily W Member 1 |
| Gene Type | Protein coding |
| Chromosomal Location | 7p22.3 |
| NCBI Gene ID | 54904 ncbi.nlm.nih.gov/gene/54904 |
| Ensembl ID | ENSG00000106483 |
| UniProt ID | Q8TAV3 |
| OMIM ID | 615967 |
| HGNC ID | 26300 |
| Aliases | CPDW1, P450-2W1, MGC126600 |
Description
CYP2W1 encodes a cytochrome P450 monooxygenase that is predominantly expressed in fetal and tumor tissues, with very low expression in normal adult tissues. It is involved in the oxidative metabolism of various xenobiotics and endogenous compounds. CYP2W1 has gained attention as a tumor-specific antigen and a potential target for prodrug activation in colorectal cancer therapy.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Colorectal Cancer | Overexpression of CYP2W1 in tumor cells activates prodrugs (e.g., duocarmycin analogs) leading to selective cytotoxicity | PMID: 17079494, PMID: 23349050 |
| Hepatocellular Carcinoma | Aberrant CYP2W1 expression contributes to altered drug metabolism and tumor progression | PMID: 25620005 |
| Gastric Cancer | Elevated CYP2W1 mRNA levels correlate with poor prognosis | PMID: 27323851 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Colon | 0.0 | Not detected |
| Liver | 0.0 | Not detected |
| Adrenal Gland | 0.0 | Not detected |
| Fetal Liver | 12.5 | Medium |
| Colorectal Tumor | 8.3 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HT-29 | 0.0 | No detectable expression |
| Caco-2 | 0.0 | No detectable expression |
| HCT 116 | 0.0 | No detectable expression |
| SW480 | 0.0 | No detectable expression |
| HepG2 | 0.0 | No detectable expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G (p.Met1?) | Missense | <0.01% | Likely loss of start codon; functional impact unknown |
| c.983C>T (p.Thr328Ile) | Missense | <0.01% | Reduced catalytic activity in vitro |
| c.1370G>A (p.Arg457Gln) | Missense | <0.01% | Unknown |
Mutation functional classification
Loss of Function (LOF)
p.Thr328Ile reduces catalytic activity; p.Met1? likely abolishes translation.
Gain of Function (GOF)
No gain-of-function mutations reported in COSMIC or ClinVar.
Dominant Negative (DN)
No dominant-negative mutations described.
View complete mutation data：
Gene Ontology (GO)
| • monooxygenase activity (GO:0004497) | • iron ion binding (GO:0005506) |
| • heme binding (GO:0020037) | • integral component of membrane (GO:0016021) |
| • endoplasmic reticulum membrane (GO:0005789) |
Pathways
• REACT:R-HSA-211981 – Xenobiotics
• REACT:R-HSA-211945 – Phase I – Functionalization of compounds
Protein Summary
CYP2W1 is a 55.8 kDa microsomal cytochrome P450 with 490 amino acids. It contains a conserved heme-binding domain and is localized to the endoplasmic reticulum. The protein exhibits low expression in normal adult tissues but is upregulated in several cancers, particularly colorectal cancer. It metabolizes arachidonic acid and certain xenobiotics, and its tumor-specific expression makes it a candidate for targeted cancer therapy.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CYP2W1 Knockout HEK293 Cell Line | EDJ-KQ13072 | Human | 54905 | Details Get a Quote |
| CYP2W1 Knockout HeLa Cell Line | EDJ-KQ56500 | Human | 54905 | Details Get a Quote |
| CYP2W1 Knockout A-549 Cell Line | EDJ-KQ64989 | Human | 54905 | Details Get a Quote |
| CYP2W1 Knockout HCT 116 Cell Line | EDJ-KQ73436 | Human | 54905 | Details Get a Quote |
